Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 14Radiotherapy 13Oxaliplatin 8Fluorouracil 7Gemcitabine 6Drug Therapy 6Leucovorin 5Doxorubicin 5Cytarabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5durvalumab 4Paclitaxel 4Etoposide 4Docetaxel 4Chemotherapy, Adjuvant 4Biological Therapy 4bicalutamide 3Rituximab 3Radiotherapy, Intensity-Modulated 3Polymerase Chain Reaction 3Platinum 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Gene Expression Profiling 3Dexamethasone 3Bortezomib 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡